Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group.
Feliu J, López Alvarez MP, Jaraiz MA, Constenla M, Vicent JM, Belón J, López Gómez L, de Castro J, Dorta J, González Barón M. Feliu J, et al. Among authors: constenla m. Cancer. 2000 Oct 15;89(8):1706-13. doi: 10.1002/1097-0142(20001015)89:8<1706::aid-cncr9>3.0.co;2-i. Cancer. 2000. PMID: 11042564 Clinical Trial.
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.
Vieitez JM, Valladares M, Gracia M, Gonzalez-Barón M, Martín G, Mel JR, Rodríguez R, Constenla M, Gómez Aldavarí JL, Domínguez S, Dorta J, García-Girón C, López R, Sevilla I, Esteban E, Antón LM, Peláez I, López E, Lacave AJ. Vieitez JM, et al. Among authors: constenla m. Lung Cancer. 2003 Jan;39(1):77-84. doi: 10.1016/s0169-5002(02)00387-2. Lung Cancer. 2003. PMID: 12499098 Clinical Trial.
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
Batista N, Perez-Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, Gonzalez Barón M, Villman K, Söderberg M, Ahlgren J, Casinello J, Regueiro P, Murias A. Batista N, et al. Among authors: constenla m. Br J Cancer. 2004 May 4;90(9):1740-6. doi: 10.1038/sj.bjc.6601784. Br J Cancer. 2004. PMID: 15150624 Free PMC article. Clinical Trial.
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Casal J, et al. Among authors: constenla m. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. doi: 10.1007/s00280-007-0418-7. Epub 2007 Feb 2. Cancer Chemother Pharmacol. 2007. PMID: 17273825 Clinical Trial.
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M, Alba E. Colomer R, et al. Among authors: constenla m. Cancer. 2007 Nov 15;110(10):2178-85. doi: 10.1002/cncr.23043. Cancer. 2007. PMID: 17926331 Free article.
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.
Aranda E, Valladares M, Martinez-Villacampa M, Benavides M, Gomez A, Massutti B, Marcuello E, Constenla M, Cámara JC, Carrato A, Dueñas R, Reboredo M, Navarro M, Díaz-Rubio E. Aranda E, et al. Among authors: constenla m. Ann Oncol. 2009 Feb;20(2):251-7. doi: 10.1093/annonc/mdn557. Epub 2008 Aug 20. Ann Oncol. 2009. PMID: 18718892 Free article. Clinical Trial.
77 results